Radioprotective Properties of Indralin in Combination with Monizol in the Treatment of Local Acute and Delayed Radiation Injuries Caused by Local Skin [gamma]-Irradiation

DOI 10.1007/s10517-015-3065-8

Bulletin of Experimental Biology and Medicine, Vol. 159, No. 6, October, 2015

747

PHARMACOLOGY AND TOXICOLOGY

Radioprotective Properties of Indralin in Combination with Monizol in the Treatment of Local Acute and Delayed Radiation Injuries Caused by Local Skin -Irradiation

M. V. Vasin, I. B. Ushakov, V. Yu. Kovtun, L. A. Semenova, S. N. Komarova, A. A. Galkin, and R. V. Afanasev

Translated from Byulleten Eksperimentalnoi Biologii i Meditsiny, Vol. 159, No. 6, pp. 720-722, June, 2015 Original article submitted September 18, 2014

Female rats were exposed to local -irradiation of the right hindpaw in doses of 30-50 Gy at 131-154 sGy/min dose rate. Radioprotector indralin was administered per os 15 min prior to irradiation, monizol was injected intraperitoneally 5 min after irradiation. Indralin showed marked radioprotective properties both for acute and delayed symptoms of local radiation injuries. In combination with monizol, radioprotective effect of indralin was potentiated to dose reduction factor of 1.4-1.5 both for radiation burn severity reduction and for restriction of postradiational contracture development and amputation of the irradiated limb.

Key Words: radioprotector; indralin; nitric oxide; skin radiation burn; postradiational brosis

Radioprotectors (RP) are used for attenuation of radiation injury in healthy tissues, in particular, in radio-therapy in case of local tumor irradiation. Radiotherapy can cause radiation injuries of skin, mucosa, blood vessels, and deeper tissues. Previous animal experiments demonstrated principal possibility of reducing early and delayed manifestations of skin radiation damage after local irradiation by using RP. RP amifostine is now successfully used in clinical practice abroad for attenuation of postradiation mucositis and xerostomia developing after radiation therapy of patients with head and neck tumors; dose reduction factor (DRF) for this RP is close to 1.4 [11,12]. In Russia, amifostine is used (according to the instruction for medical use of amifos-

tine) for prevention of hemotoxicity of DNA-binding chemotherapeutic agents and nephro-, neuro-, and ototoxicity of platinum compounds.

It was established experimentally that RP indralin meant for personnel protection in emergency situations also exhibits pronounced radioprotective properties against -irradiation of the skin and underlying tissues and acute and delayed symptoms of local radiation injury (LRI) [3,5] comparable to those of amifostine.

The aim of this study was to analyze the radioprotective effect of indralin in LRI administered in combination...